Close

Exelixis (EXEL) to Present Phase 3 CELESTIAL Trial Results of Cabozantinib at 2018 ASCO-GI Symposium

November 22, 2017 5:41 AM EST Send to a Friend
Exelixis, Inc. (NASDAQ: EXEL) today announced that the phase 3 CELESTIAL trial results have been accepted as a late-breaking presentation ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login